A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
This is a first-in-human to learn more about the investigational drug of NX-1607 in patients with advanced malignancies.
Why this Research Matters
This study is being done to see if NX-1607 is safe and tolerated, and to find the highest does that can safely be given. The study will also look at whether NX-1607 has an effect on the cancers being studied.
Who can Participate
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Study ID
Protocol Number: 23-1337
More information available at ClinicalTrials.gov: NCT05107674
Meet the Team
Principal Investigator